Ken Griffin Pmv Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.51 - $2.21 $2,265 - $3,315	-1,500 Reduced 78.95%	400 $0
Q1 2024 May 15, 2024	SELL	$1.51 - $3.12 $6,946 - $14,352	-4,600 Reduced 70.77%	1,900 $3,000
Q4 2023 Feb 14, 2024	SELL	$1.23 - $6.6 $8,733 - $46,860	-7,100 Reduced 52.21%	6,500 $20,000
Q3 2023 Nov 14, 2023	BUY	$6.01 - $8.93 $71,519 - $106,267	11,900 Added 700.0%	13,600 $83,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $6.27 $5,516 - $8,778	1,400 Added 466.67%	1,700 $10,000
Q1 2023 May 15, 2023	SELL	$4.77 - $9.16 $38,637 - $74,196	-8,100 Reduced 96.43%	300 $1,000
Q4 2022 Feb 14, 2023	BUY	$8.17 - $12.95 $68,628 - $108,780	8,400 New	8,400 $73,000

43.4M

500

100

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $76.2M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.